Ruth Rincón-Heredia

Ruth Rincón-Heredia

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2015 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
LCLucy Camberos-Luna
Lucy Camberos-Luna
CGCristian Gerónimo-Olvera
Cristian Gerónimo-Olvera
TMTeresa Montiel
Teresa Montiel
RRRuth Rincón-Heredia
Ruth Rincón-Heredia
LMLourdes Massieu
Lourdes Massieu

4 June 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ILIsabel Larre
Isabel Larre
ALAmparo Lazaro
Amparo Lazaro
RCRubén G. Contreras
Rubén G. Contreras
Maria Susana BaldaMaria Susana Balda
Maria Susana Balda
Karl MatterKarl Matter
Karl Matter
MCMarcelino Cereijido
Marcelino Cereijido
Epithelial cells treated with high concentrations of ouabain (e.g., 1 μM) retrieve molecules involved in cell contacts from the plasma membrane and detach from one another and their substrates. On the basis of this observation, we suggested that ouabain might also modulate cell contacts at low, nontoxic levels (10 or 50 nM). To test this possibility, we analyzed its effect on a particular type of cell–cell contact: the tight junction (TJ). We demonstrate that at concentrations that neither inhibit K + pumping nor disturb the K + balance of the cell, ouabain modulates the degree of sealing of the TJ as measured by transepithelial electrical resistance (TER) and the flux of neutral 3 kDa dextran (J DEX ). This modulation is accompanied by changes in the levels and distribution patterns of claudins 1, 2, and 4. Interestingly, changes in TER, J DEX , and claudins behavior are mediated through signal pathways containing ERK1/2 and c-Src, which have distinct effects on each physiological parameter and claudin type. These observations support the theory that at low concentrations, ouabain acts as a modulator of cell–cell contacts.

9 June 2014 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
VGVicky García‐Hernández
Vicky García‐Hernández
CFCatalina Flores‐Maldonado
Catalina Flores‐Maldonado
RRRuth Rincón-Heredia
Ruth Rincón-Heredia
OVOdette Verdejo‐Torres
Odette Verdejo‐Torres
José Bonilla-DelgadoJosé Bonilla-Delgado
José Bonilla-Delgado
RCRubén G. Contreras
Rubén G. Contreras

1 January 2017 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
ECEibar Ernesto Cabrera-Aldana
Eibar Ernesto Cabrera-Aldana
FRFernando Ruelas
Fernando Ruelas
CACristina Aranda
Cristina Aranda
RRRuth Rincón-Heredia
Ruth Rincón-Heredia
AMAngelina Martínez-Cruz
Angelina Martínez-Cruz
LRLuis B. Tovar Y Romo
Luis B. Tovar Y Romo
Spinal cord injury (SCI) is an incapacitating condition that affects motor, sensory, and autonomic functions. Since 1990, the only treatment administered in the acute phase of SCI has been methylprednisolone (MP), a synthetic corticosteroid that has anti-inflammatory effects; however, its efficacy remains controversial. Although MP has been thought to help in the resolution of edema, there are no scientific grounds to support this assertion. Aquaporin 4 (AQP4), the most abundant component of water channels in the CNS, participates in the formation and elimination of edema, but it is not clear whether the modulation of AQP4 expression by MP plays any role in the physiopathology of SCI. We studied the functional expression of AQP4 modulated by MP following SCI in an experimental model in rats along with the associated changes in the permeability of the blood-spinal cord barrier. We analyzed these effects in male and female rats and found that SCI increased AQP4 expression in the spinal cord white matter and that MP diminished such increase to baseline levels. Moreover, MP increased the extravasation of plasma components after SCI and enhanced tissue swelling and edema. Our results lend scientific support to the increasing motion to avoid MP treatment after SCI.

7 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SRSayonarah C. Rocha
Sayonarah C. Rocha
MPMarco T. C. Pessoa
Marco T. C. Pessoa
LNLuiza D. R. Neves
Luiza D. R. Neves
SASilmara L. G. Alves
Silmara L. G. Alves
LSLuciana M. Silva
Luciana M. Silva
LBLeandro Barbosa
Leandro Barbosa
Cardiotonic steroids are used to treat heart failure and arrhythmia and have promising anticancer effects. The prototypic cardiotonic steroid ouabain may also be a hormone that modulates epithelial cell adhesion. Cardiotonic steroids consist of a steroid nucleus and a lactone ring, and their biological effects depend on the binding to their receptor, Na,K-ATPase, through which, they inhibit Na+ and K+ ion transport and activate of several intracellular signaling pathways. In this study, we added a styrene group to the lactone ring of the cardiotonic steroid digoxin, to obtain 21-benzylidene digoxin (21-BD), and investigated the effects of this synthetic cardiotonic steroid in different cell models. Molecular modeling indicates that 21-BD binds to its target Na,K-ATPase with low affinity, adopting a different pharmacophoric conformation when bound to its receptor than digoxin. Accordingly, 21-DB, at relatively high µM amounts inhibits the activity of Na,K-ATPase α1, but not α2 and α3 isoforms. In addition, 21-BD targets other proteins outside the Na,K-ATPase, inhibiting the multidrug exporter Pdr5p. When used on whole cells at low µM concentrations, 21-BD produces several effects, including: 1) up-regulation of Na,K-ATPase expression and activity in HeLa and RKO cancer cells, which is not found for digoxin, 2) cell specific changes in cell viability, reducing it in HeLa and RKO cancer cells, but increasing it in normal epithelial MDCK cells, which is different from the response to digoxin, and 3) changes in cell-cell interaction, altering the molecular composition of tight junctions and elevating transepithelial electrical resistance of MDCK monolayers, an effect previously found for ouabain. These results indicate that modification of the lactone ring of digoxin provides new properties to the compound, and shows that the structural change introduced could be used for the design of cardiotonic steroid with novel functions.

1 January 2014 in Experimental Cell Research
Verified
Journal Article
Closed access
RRRuth Rincón-Heredia
Ruth Rincón-Heredia
DFDavid Flores-Benitez
David Flores-Benitez
CFCatalina Flores-Maldonado
Catalina Flores-Maldonado
José Bonilla-DelgadoJosé Bonilla-Delgado
José Bonilla-Delgado
VGVicky García-Hernández
Vicky García-Hernández
RCRubén G. Contreras
Rubén G. Contreras